Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Resmed reported Q1 FY27 revenue of $1.415 billion, up 6% year-over-year (7% core constant currency), with GAAP diluted EPS of $2.92, up 23%, and non-GAAP diluted EPS of $2.91, up 14%. Non-GAAP gross margin expanded 50 bps to 62.5%, and free cash flow was $374 million; proceeds from the closed MatrixCare divestiture helped fund more than $1.0 billion returned to shareholders via buybacks and dividends. FY27 guidance was reaffirmed: 5-7% core constant currency revenue growth, reported revenue of $5.75-$5.85B, and non-GAAP EPS of $12.00-$12.25.
Key figures
- Eps
- 2.92
- Revenue
- 1415000000
- Guidance
- FY27 core constant currency revenue growth 5-7%, reported revenue $5.75-$5.85B, non-GAAP diluted EPS $12.00-$12.25 (all unchanged from August 6, 2026 guidance)
- Revenue Yoy
- 6%
- Fcf
- 374000000
- Eps yoy
- 23%
- Net income
- 418000000
- Non gaap eps
- 2.91
- Non gaap eps yoy
- 14%
- Operating income
- 453000000
- Gaap gross margin
- 61.5%
- Quarterly dividend
- $0.66 per share
- Operating cash flow
- 422000000
- Shareholder returns
- $1.0 billion returned via dividends and buybacks
- Non gaap gross margin
- 62.5%
- Non gaap operating margin
- 35.8%
- Core constant currency revenue growth
- 7%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.